Search | Clinical Trials Finder

Conditions: Autism Spectrum Disorder, Autism, ASD, Autism Spectrum Disorder (ASD)
Interventions: Umbilical Cord Blood-Derived Stem Cells and Exosomes, Glutathione; Biological · Drug
Lead sponsor: Adia Med of Winter Park LLC; Other
Eligibility: 3 Years to 12 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Winter Park, Florida • Green Bay, Wisconsin

Conditions: Myelodysplastic Syndrome (MDS)
Interventions: Ezatiostat Hydrochloride; Drug
Lead sponsor: Telik; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 36
States / cities: Tucson, Arizona • Alhambra, California • Fullerton, California + 30 more

Conditions: Leukemia, Pediatric Acute Lymphoblastic Leukemia, Pediatric Acute Lymphoblastic Leukemia in Remission, Pediatric Obesity
Interventions: Modified Guided Self-Help Family Intervention, NIH Educational Resources, FitBit Ace, WashU Extended Learning Canvas; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 6 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer
Interventions: high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry, medical chart review; Other
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 2
States / cities: Rochester, Minnesota • Omaha, Nebraska

Conditions: Pyruvate Dehydrogenase Complex Deficiency
Interventions: Dichloroacetate (DCA), Placebo, Genotype; Drug · Other · Genetic
Lead sponsor: Saol Therapeutics Inc; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 10
States / cities: Orange, California • Stanford, California • Washington D.C., District of Columbia + 7 more

Conditions: Glutathione-cyclodextrin Complex Absorption
Interventions: Glutaryl Solution, Placebo Solution; Dietary Supplement
Lead sponsor: Western University of Health Sciences; Other
Eligibility: 21 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Pomona, California

Conditions: Ovarian Cancer
Interventions: NOV-002, Carboplatin; Drug
Lead sponsor: Cellectar Biosciences, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Glioblastoma Multiforme, Recurrent Glioma
Interventions: Normal diet, Cysteine/methionine deprivation (CMD) diet for 2 days, Cysteine/methionine deprivation (CMD) diet for 4 days; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Parkinson Disease
Interventions: N-acetylcysteine, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 50 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Mild Cognitive Impairment (MCI)
Interventions: Gamma- Glutamylcysteine, Gamma- Glutamylcusteine; Drug
Lead sponsor: Pravat Mandal; Other
Eligibility: 55 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hookworm Infections
Interventions: Na-GST-1/Alhydrogel, Na-GST-1/Alhydrogel + CPG 10104, Na-GST-1/Alhydrogel + GLA-AF, Placebo, Albendazole, Necator americanus Larval Inoculum; Biological · Drug · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 45 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Type I Diabetes Mellitus
Interventions: Glutamine, Placebo; Dietary Supplement
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 13 Years to 19 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Renal Failure, Coronary Artery Disease, Surgery, Surgery-Complications
Interventions: CoQ10 1200 mg orally with Glutathione 1000 mg orally, Group B: Placebo CoQ10 orally and Placebo Glutathione orally; Drug
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Obsessive-Compulsive Disorder
Interventions: "OCFighter"; Behavioral
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years to 69 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Repetitive Head Impacts
Interventions: Gamma-glutamylcysteine (GGC); Drug
Lead sponsor: Pravat Mandal; Other
Eligibility: 30 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Oxidative Stress
Interventions: Placebo low dose, N Acetyl cysteine, 600mg (low dose), Proimmune 200 (FT061452) 3000mg low dose, Placebo (high dose), N Acetyl cysteine, 1200mg (high dose), FT061452, 6000mg high dose; Drug
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 30 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Vitamin B6 Deficiency
Interventions: Arm 1 glycine and leucine, Arm 2 Intervention of Serine and methionine infusion; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 20 Years to 40 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Parkinson's Disease
Interventions: Reduced Glutathione 100mg, Reduced Glutathione 200mg, Placebo; Drug
Lead sponsor: Bastyr University; Other
Eligibility: 21 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Kenmore, Washington • Seattle, Washington

Conditions: Myelodysplastic Syndrome
Interventions: Ezatiostat Hydrochloride, Lenalidomide (Revlimid®); Drug
Lead sponsor: Telik; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 9
States / cities: Phoenix, Arizona • Maywood, Illinois • Bethesda, Maryland + 6 more

Conditions: Leukemia, Myelodysplastic Syndromes, Sarcoma
Interventions: clonality analysis, microsatellite instability analysis, mutation analysis; Genetic
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 17 Years
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2007
U.S. locations: 83
States / cities: Downey, California • Long Beach, California • Los Angeles, California + 72 more

Conditions: Non-cystic Fibrosis Bronchiectasis
Interventions: ARINA-1, Placebo; Drug
Lead sponsor: Renovion, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Birmingham, Alabama • Denver, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Busulfan Pharmacokinetic Analysis, Busulfan Dosing, Hematopoietic Stem Cell Transplant (HSCT), Busulfan, Glutathione
Interventions: Busulfan (BU); Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 21 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Autistic Disorder
Interventions: B12, Placebo, folate, B complex, vitamin C, cod liver oil, Mineral complex, carnitine; Dietary Supplement
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 3 Years to 7 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Pre-Bronchiolitis Obliterans Syndrome
Interventions: ARINA-1, Standard of care only; Drug · Other
Lead sponsor: Renovion, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 17 more

Search by objective public record fields.

Adia Med of Winter Park LLC Autism Spectrum Disorder Research Study

Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)

Weight Gain in Pediatric Leukemia Survivors

Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Treated for Newly Diagnosed Breast Cancer

Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:

Topical Absorption of Glutathione-cyclodextrin Complex in Healthy Human Subjects Improves Immune Response Against Mycobacterium Infection

Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer

Dietary Cysteine and Methionine Deprivation (CMD) in Glioma Patients

N-Acetylcysteine for Neuroprotection in Parkinson's Disease

Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients

Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection

Glutamine and Insulin Sensitivity in Type I Diabetes

Prevent Cardiac Surgery Associated AKI Trial

Effectiveness and Neuropsychological Predictors of Guided Self-Help for Obsessive-Compulsive Disorder (OCD)

Monitoring Patients With Repetitive Head Impact With Gamma-glutamylcysteine Supplementation

The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels

Vitamin B6 Dependence of One-Carbon Metabolism

Phase IIb Study of Intranasal Glutathione in Parkinson's Disease

Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Genetic Study of Children With Soft Tissue Sarcoma or Rhabdomyosarcoma

Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough

26DT052; Scaling Busulfan Dose to Body Surface Area in Children

Treating Oxidative Stress and the Metabolic Pathology of Autism

Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant